Autonomix Medical, Inc. — fact timeline

Autonomix Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital”

Autonomix Medical, Inc. issued Series C Warrants to purchase up to an aggregate of 9,003,332 shares of Common Stock of warrant to institutional investor for combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $1.1097.

“and Pre-Funded Warrants are collectively referred to herein as the “Warrants”. The combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $1.1097. Subject to certain ownership limitations, the Warrants are exercisable immediately upon issuance (the “Initial Exercise Date”). Each Pre-Funded Warrant is exercisable into one”

Autonomix Medical, Inc. issued Pre-Funded Warrants to purchase 4,501,666 shares of warrant to institutional investor for combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $1.1097.

“and Pre-Funded Warrants are collectively referred to herein as the “Warrants”. The combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $1.1097. Subject to certain ownership limitations, the Warrants are exercisable immediately upon issuance (the “Initial Exercise Date”). Each Pre-Funded Warrant is exercisable into one”

Autonomix Medical, Inc.: Approved an amendment to the certificate of incorporation to effect a 1-for-20 reverse stock split of common stock (effective 2024-10-24).

“The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 11:59 p.m. Eastern Time on October 24, 2024 (the “Effective Time”), and the Company’s common stock will open for trading on The Nasdaq Capital Market on October 25, 2024 on a post-split basis, under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T205.”

Brad Hauser was appointed as chief executive officer and president at Autonomix Medical, Inc..

“entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as the Company’s chief executive officer and president”